Aldoril D30 Side Effects

Generic Name: hydrochlorothiazide / methyldopa

Note: This page contains information about the side effects of hydrochlorothiazide / methyldopa. Some of the dosage forms included on this document may not apply to the brand name Aldoril D30.

Not all side effects for Aldoril D30 may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to hydrochlorothiazide / methyldopa: oral tablet

In addition to its needed effects, some unwanted effects may be caused by hydrochlorothiazide / methyldopa. In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking hydrochlorothiazide / methyldopa:

Rare
  • Unexplained fever shortly after starting to take this medicine

If any of the following side effects occur while taking hydrochlorothiazide / methyldopa, check with your doctor or nurse as soon as possible:

Signs and symptoms of too much potassium loss
  • Dry mouth
  • increased thirst
  • irregular heartbeats
  • muscle cramps or pain
  • nausea or vomiting
  • unusual tiredness or weakness
  • weak pulse
Less common
  • Mental depression or anxiety
  • nightmares or unusually vivid dreams
Rare
  • Cough or hoarseness
  • dark or amber urine
  • diarrhea or stomach cramps (severe or continuing)
  • fever, chills, troubled breathing, and fast heartbeat
  • general feeling of discomfort or illness or weakness
  • joint pain
  • lower back or side pain
  • painful or difficult urination
  • pale stools
  • skin rash, hives, or itching
  • stomach pain (severe) with nausea and vomiting
  • tiredness or weakness after having taken this medicine for several weeks (continuing)
  • yellow eyes or skin

Some of the side effects that can occur with hydrochlorothiazide / methyldopa may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common
  • Dizziness or light-headedness when getting up from a lying or sitting position
  • drowsiness
  • dryness of mouth
  • headache
Less common
  • Decreased sexual ability or interest in sex
  • diarrhea
  • increased sensitivity of skin to sunlight (skin rash, itching, redness or other discoloration of skin or severe sunburn after exposure to sunlight)
  • loss of appetite
  • numbness, tingling, pain, or weakness in hands or feet
  • slow heartbeat
  • stuffy nose
  • swelling of breasts or unusual milk production

For Healthcare Professionals

Applies to hydrochlorothiazide / methyldopa: oral tablet

Hepatic

The mechanism of methyldopa hepatotoxicity is believed to be delayed hypersensitivity, although some speculate an accumulation of metabolites which are directly hepatotoxic in late onset cases.

A 78-year-old woman with hypertension and diabetes developed acute renal failure and a clinical picture of sepsis while taking methyldopa. Autopsy revealed disseminated nonnecrotizing granulomas throughout her liver, spleen, lung, lymph nodes, and bone marrow, as well as findings of myocarditis. There was no evidence of infection, including tuberculosis.

A 75-year-old man with hypertension developed severe cholestatic liver disease six years after beginning methyldopa 250 mg per day. There was no evidence of viral or obstructive disease.[Ref]

Hepatic toxicity may be highly significant. Transient elevations of liver function tests are seen in 5% of patients who are taking methyldopa. Symptomatic hepatitis, usually resembling viral hepatitis, is uncommon. Usually beginning within the first four weeks of therapy, the syndrome typically presents as a fever, followed by icterus, weakness, nausea, and abdominal pain. It usually resolves within three weeks after drug withdrawal, but rare cases of chronic hepatitis have been reported. Granulomatous hepatitis is a rare manifestation of methyldopa hepatotoxicity. Alternative therapy is recommended in patients with liver cirrhosis or acute hepatitis due to the risk of additional hepatotoxicity associated with methyldopa.[Ref]

Hematologic

Hematologic abnormalities include hemolytic anemia due to a methyldopa-provoked autoantibody with associated positive direct Coombs test in 10% to 20% of patients on chronic therapy. Cases of neutropenia, pure red blood cell aplasia, thrombocytopenia, positive LE cells, and elevated rheumatoid factor have been reported. Rare cases of immune-complex hemolytic anemia, aplastic anemia, and thrombocytopenia have been associated with hydrochlorothiazide (HCTZ).[Ref]

In one case of methyldopa-associated neutropenia, a methyldopa-dependent antibody against granulocytes was isolated.

A 75-year-old man with hypertension developed pure red blood cell aplasia within three months after starting methyldopa therapy. The Coombs test and immunoglobulin levels were normal; bone marrow biopsy revealed an absence of erythroid precursors. There was no evidence of hemolysis or infection. Erythroblastosis was observed within five days after drug withdrawal.

A 70-year-old woman with diabetes and hypertension developed thrombocytopenia and an elevated ANA titer associated with methyldopa. Unfortunately, the thrombocytopenia was complicated by a thrombotic stroke. Her platelet count and ANA titer resolved upon substitution with nifedipine. In some cases of methyldopa-associated thrombocytopenia an antiplatelet lgG antibody has been isolated.

There are rare case reports of HCTZ-induced immune hemolytic anemia. The following illustrates a fatal case:

A 53-year-old man with hypertension developed nausea, vomiting, diarrhea, and progressive anorexia and weakness associated with scleral icterus, anemia with spherocytosis, dark red urine with proteinuria, bilirubinuria, and hemoglobinuria, and elevated lactic dehydrogenase levels 18 months after beginning HCTZ and methyldopa. Haptoglobin was less than 50 mg per dL. Direct and indirect Coombs tests were positive. The patient died suddenly; autopsy revealed no obvious cause of death, left ventricular hypertrophy, and mild coronary atherosclerosis.[Ref]

Cardiovascular

Cardiovascular problems include hypotension in up to 10% and sinus and AV nodal conduction disturbances in 0.2% of patients. HCTZ-induced hypokalemia can predispose some patients to develop significant arrhythmias, including ventricular ectopy and complete AV heart block. Hypotension and methyldopa-induced carotid sinus hypersensitivity can result in syncope in some patients. Rare cases of paradoxical hypertension or myocarditis (in association with hepatitis or pneumonitis) have been associated with methyldopa.[Ref]

A 58-year-old man with hypertension and coronary artery disease experienced transient asystole during carotid massage during methyldopa therapy. The abnormality resolved upon discontinuation of the drug and was reproducible on rechallenge.

A 75-year-old man with chronic obstructive pulmonary disease and hypertension developed new signs and symptoms of congestive heart failure associated with new complete AV heart block while taking methyldopa. Six days after stopping the drug, normal sinus rhythm returned. Rechallenge resulted in recurrent complete AV heart block.[Ref]

Metabolic

Since HCTZ may increase total serum cholesterol by 11%, LDL lipoprotein cholesterol by 12%, VLDL lipoprotein cholesterol by 50%, and may reduce insulin secretion, it should be used with caution in diabetic patients and in those with hypercholesterolemia.

Hyperuricemia may be an important consideration in patients with a history of gout. Hypophosphatemia and low serum magnesium concentrations may occur, but are usually clinically insignificant except in malnourished patients.[Ref]

Metabolic side effects are commonly associated with HCTZ, especially when doses greater than 50 mg per day are used. Mild hypokalemia (decrease of 0.5 mEq/L) occurs in up to 50% of patients, and may predispose some to develop arrhythmias. Metabolic alkalosis, hyponatremia, hypomagnesemia, hypercalcemia, hyperglycemia, hypercholesterolemia, and elevated serum uric acid levels are also relatively common problems during HCTZ therapy.[Ref]

Immunologic

A 55-year-old man with hypertension developed hemolytic anemia, arthritis, and photosensitivity associated with an ANA against class H1 histones 13 months after beginning methyldopa. The syndrome and laboratory abnormalities resolved after drug discontinuation and steroid therapy.[Ref]

Immunologic changes have been associated with methyldopa. The drug can induce the development of a positive antinuclear antibody (ANA) titer. Rare cases of a lupus syndrome, retroperitoneal fibrosis and lymphadenopathy have been reported.[Ref]

Hypersensitivity

Two cases of methyldopa-associated profound hypotension, fever, chills, and diarrhea associated with a leukocytosis and negative blood cultures have been reported in elderly patients. In each case rechallenges were positive.

A 68-year-old man with a history of myocardial infarction (MI) developed dyspnea, chest tightness, a low grade fever, dizziness, sweating, and vomiting associated with cyanosis, a mild leukocytosis, radiographic evidence of pulmonary edema, clinical evidence of hypovolemia, and respiratory acidosis. MI and infection were ruled out; the patient recovered after restoration of intravascular volume with saline and albumin. The only precipitating factor per history was the ingestion of HCTZ, which the patient had taken without incident for two years. Rechallenge resulted in recurrent acute pulmonary edema. Other signs of hypersensitivity, such as rash and eosinophilia, were absent.[Ref]

Hypersensitivity reactions to either drug are rare, but may be severe. A syndrome consisting of nausea, vomiting, diarrhea, and rash has been reported in less than 1% of patients who are taking HCTZ. There have also been rare cases of acute pulmonary edema, interstitial cystitis or nephritis, and anaphylaxis associated with HCTZ and rare cases of vasculitis, rash, drug fever, and anaphylactoid-like reactions associated with methyldopa.[Ref]

Nervous system

Nervous system complaints are probably due to methyldopa, and include dizziness in up to 19%, general fatigue in 1% to 10%, insomnia in less than 5%, and headache in 2% of patients. New choreoathetotic movements and exacerbations of parkinsonian symptoms have rarely been associated with the drug. Rare cases of cerebrovascular insufficiency have been associated with HCTZ-induced plasma volume contraction.[Ref]

Dermatologic

Dermatologic reactions associated with HCTZ include erythema annular centrifugum, acute eczematous dermatitis, and morbilliform and leukocytoclastic vasculitis. Reports of hyperpigmentation, nodular rashes, and lichenoid eruptions have been associated with methyldopa. Either drug may induce phototoxic dermatitis. In addition, a rare, distinct entity with clinical and laboratory features indistinguishable from those of subacute cutaneous lupus erythematosus has been associated with HCTZ.[Ref]

A 67-year-old white woman with hypothyroidism, hypercalcemia, depression, and hypertension developed facial erythema, headaches, tremors, confusion, personality changes associated with a new positive ANA and anti-nRNP, and skin biopsy consistent with lupus erythematosus while taking HCTZ, levothyroxine, and amitriptyline. The eruption resolved upon discontinuation of HCTZ, but she later developed a higher ANA titer associated with symptomatic diffuse interstitial pulmonary infiltrates. She was successfully treated with corticosteroids.[Ref]

Renal

Renal side effects including new or worsened renal insufficiency may occur due to HCTZ-induced intravascular volume depletion. Rare cases of interstitial nephritis have been associated with HCTZ.[Ref]

Although HCTZ has been used to treat nephrogenic diabetes insipidus, a case report in which the drug was believed to have caused this condition has been reported.[Ref]

Gastrointestinal

A 68-year-old man with hypertension developed diabetic ketoacidosis (DKA) four weeks after beginning methyldopa 1000 mg per day. Naive rechallenge of the drug ten months later resulted in recurrent DKA associated with ultrasonographic evidence of pancreatitis. The patient later showed signs of chronic pancreatitis, including weight loss, steatorrhea, and pancreatic calcification.

Thiazide diuretics may increase serum cholesterol and triglycerides, resulting in increased risk of cholesterol gallstone formation. Reports of bowel strictures associated with thiazide ingestion have been reported in the 1960's, although these patients were on a combination HCTZ-potassium product.[Ref]

Gastrointestinal side effects include diarrhea or nausea in 1% to 5% of patients who are taking methyldopa. A case of "black tongue" has been associated with methyldopa, and rare cases of acute cholecystitis, pancreatitis, or colitis have been associated with either drug.[Ref]

Endocrine

An 81-year-old man with hypertension developed hyponatremia associated with a urine to serum osmolality ratio of 1.5. A standard water test with and without methyldopa revealed less free water excretion with the drug than without.

Interestingly, the patient's bone marrow revealed noncaseating granulomas; there was no evidence of thyroid, adrenal, pulmonary, cardiac, or CNS disease, and no evidence of tuberculosis infection. The patient's hyponatremia, abnormal liver function tests, and abnormal bone marrow findings normalized upon withdrawal of methyldopa.

Limited data show transient reductions in HDL lipoprotein cholesterol of approximately 10% in middle-aged men with hypertension who were taking methyldopa. Over time, however, this reduction tended to revert to baseline values.

A prospective study of 34 patients who received oral thiazide diuretics for 14 years without interruption revealed an increased mean fasting blood glucose level after treatment. Withdrawal of thiazide therapy for 7 months in 10 of the patients resulted in mean reductions of 10% in fasting blood glucose and 25% in the 2-hour glucose tolerance test value. A control group was not reported.[Ref]

Endocrinologic problems, such as amenorrhea or galactorrhea, resulting from methyldopa-induced hyperprolactinemia have been reported. Endocrinologic problems associated with thiazide diuretics include glucose intolerance and a potentially deleterious effect on the lipid profile. This may be important in some patients with or who are at risk for diabetes or coronary artery disease. A case of inappropriate secretion of antidiuretic hormone has been associated with methyldopa.[Ref]

Respiratory

A 27-year-old chemist who manufactured methyldopa developed nasal congestion, sneezing, and exertional wheezing associated with a demonstrable fall of the FEV1 by 30%. Her signs and symptoms resolved when the environmental exposure to methyldopa was removed. No antibodies to methyldopa were found.[Ref]

Respiratory system problems are rare. Nasal congestion has been reported in less than 5% of patients who are taking methyldopa. A rare case of bronchospasm is reported in a chemist involved in the manufacture of methyldopa. There have been approximately 30 case reports of acute noncardiogenic pulmonary edema associated with HCTZ.[Ref]

Psychiatric

A 62-year-old man developed mania within 4 weeks after switching from methyldopa to nifedipine antihypertensive therapy.

In one study of 41 elderly patients, ages 75 to 85, without pretreatment dementia, who were treated with methyldopa, decreased ability to perform object assembly tasks were noted, but depression was no more likely than with placebo.[Ref]

Psychiatric side effects are unusual. Depression occurs in 2% of patients who are taking methyldopa. There have also been rare cases of paranoia and forgetfulness associated with methyldopa, particularly in the elderly.[Ref]

Genitourinary

Genitourinary complaints of impotence among male patients who are taking methyldopa is rarely reported, but may be underdiagnosed. Limited data suggest that methyldopa may precipitate in urine in some patients, providing the nidus for calcium phosphate calculi.[Ref]

In one study of 258 men who were taking methyldopa, 16% reported impotence. In one study of 27 males with hypertension, 7 complained of decreased libido, inability to sustain erections and difficulty in ejaculation.[Ref]

References

1. Puppala AR, Steinheber FU "Fulminant hepatic failure associated with methyldopa." Am J Gastroenterol 68 (1977): 579-81

2. Furhoff AK "Adverse reactions with methyldopa: a decade's reports." Acta Med Scand 203 (1978): 425-8

3. Cacace LG, Cohen M "Alpha-methyldopa (aldomet) hepatitis." Drug Intell Clin Pharm 10 (1976): 144-52

4. Valnes K, Hillestad L, Hansen T, Arnold E "Alpha-methyldopa and drug fever." Acta Med Scand 204 (1978): 21-5

5. Thomas E, Rosenthal WS, Zapiach L, Micci D "Spectrum of methyldopa liver injury." Am J Gastroenterol 68 (1977): 125-33

6. Matteson EL, Palella TD "Alpha-methyldopa-induced systemic vasculitis confused with Wegener's granulomatosis." Arthritis Rheum 32 (1989): 356-7

7. Miller AC, Reid WM "Methyldopa-induced granulomatous hepatitis." JAMA 235 (1976): 2001-2

8. Rodman JS, Deutsch DJ, Gutman SI "Methyldopa hepatitis: a report of six cases and review of the literature." Am J Med 60 (1976): 941-8

9. Goldstein GB, Lam KC, Mistillis SP "Drug-induced active chronic hepatitis." Dig Dis 18 (1973): 177-84

10. Carr AA, Mulligan OF, Sherrill LN "Pindolol versus methyldopa for hypertension: comparison of adverse reactions." Am Heart J 104 (1982): 479-81

11. Moses A, Zahger D, Amir G "Cholestatic liver injury after prolonged exposure to methyldopa." Digestion 42 (1989): 57-60

12. Neuberger J, Kenna JG, Aria KN, Williams R "Antibody mediated hepatocyte injury in methyldopa induced hepatotoxicity." Gut 26 (1985): 1233-9

13. Bonkowsky HL, Brisbane J "Colitis and hepatitis caused by methyldopa." JAMA 236 (1976): 1602-3

14. Horwitz D, Pettinger WA, Orvis H, et al "Effects of methyidopa in fifty hypertensive patients." Clin Pharmacol Ther 8 (1967): 224-34

15. Seeverens H, de Bruin CD, Jordans JG "Myocarditis and methyldopa." Acta Med Scand 211 (1982): 233-5

16. Sotaniemi EA, Hokkanen OT, Ahokas JT, et al "Hepatic injury and drug metabolism in patients with alpha-methyldopa-induced liver damage." Eur J Clin Pharmacol 12 (1977): 429-35

17. Bezahler GH "Case report: fatal methyldopa-associated granulomatous hepatitis and myocarditis." Am J Med Sci 283 (1982): 41-5

18. Paj RG, Paj SM "Methyldopa-induced reversible immune thrombocytopenia." Am J Med 85 (1988): 123

19. Roy A, Ghosh ML "Coombs positive haemolytic anaemia due to methyldopa." Br J Clin Pract 35 (1981): 54, 58

20. Garratty G, Houston M, Petz LD, Webb M "Acute immune intravascular hemolysis due to hydrochlorothiazide." Am J Clin Pathol 76 (1981): 73-8

21. Distenfeld A, Florita C, Gelfand ML "Hemolytic anemia induced by alpha-methyldopa." N Y State J Med Feb (1970): 570-3

22. Itoh K, Wong P, Asai T, et al "Pure red cell aplasia induced by alpha-methyldopa." Am J Med 84 (1988): 1088-9

23. Devereux S, Fisher DM, Roter BL, Hegde UM "Factor VIII inhibitor and raised platelet IgG levels associated with methyldopa therapy." Br J Haematol 54 (1983): 485-8

24. Eisner EV, Crowell EB "Hydrochlorothiazide-dependent thrombocytopenia due to IgM antibody." JAMA 215 (1971): 480-2

25. Marcus GJ, Stevenson M, Brown T "Alpha-methyldopa-induced immune thrombocytopenia." Am J Clin Pathol 64 (1975): 113-5

26. Lawson DH, Gloss D, Jick H "Adverse reactions to methyldopa with particular reference to hypotension." Am Heart J 96 (1978): 572-9

27. Varkel Y, Braester A, Nusem D, Shkolnik T "Methyldopa-induced syndrome of inappropriate antidiuretic hormone-secretion and bone marrow granulomatosis." Drug Intell Clin Pharm 22 (1988): 700-1

28. Closs SP, Cummins D, Contreras M, Armitage SE "Neutropenia due to methyldopa antibodies." Lancet June (1984): 1479

29. Beck ML, Cline JF, Hardman JT, Racela LS, Davis JW "Fatal intravascular immune hemolysis induced by hydrochlorothiazide." Am J Clin Pathol 81 (1984): 791-4

30. "Product Information. Aldoril (methyldopa-hydrochlorothiazide)." Merck & Co, Inc, West Point, PA.

31. Papademetriou V, Fletcher R, Khatri IM, Freis ED "Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias." Am J Cardiol 52 (1983): 1017-22

32. Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73

33. Cokkinos DV, Vorides EM "Impairment of atrioventricular conduction by methyldopa." Chest 74 (1978): 697

34. Mahabir RN, Laufer ST "Clinical evaluation of diuretics in congestive heart failure. A detailed study in four patients." Arch Intern Med 124 (1969): 1-7

35. Zehnle CG "Paradoxical hypertension experienced during methyldopa therapy." Am J Hosp Pharm 38 (1981): 1774-5

36. Krishna GG, Narins RG "Hemodynamic consequences of diuretic-induced hypokalemia." Am J Kidney Dis 12 (1988): 329-31

37. Rosen B, Ovsyshcher IA, Zimlichman R "Complete atrioventricular block induced by methyldopa." Pacing Clin Electrophysiol 11 (1988): 1555-8

38. Hollifield JW, Slaton PE "Thiazide diuretics, hypokalemia and cardiac arrhythmias." Acta Med Scand Suppl 647 (1981): 67-73

39. Ferris JA, Rice J "Drug-induced myocarditis: a report of two cases." Forensic Sci Int 13 (1979): 261-5

40. Grunwald MH, Halevy S, Livni E "Allergic vasculitis induced by hydrochlorothiazide: confirmation by mast cell degranulation test." Isr J Med Sci 25 (1989): 572-4

41. Cregler LL, Mark H "Second-degree atrioventricular block and alpha-methyldopa: a probable connection." Mt Sinai J Med 54 (1987): 168-70

42. Mouallem M, Friedman E, Shemesh Y, Mayan H, Pauzner R, Farfel Z "Cardiac conduction defects associated with hyponatremia." Clin Cardiol 14 (1991): 165-8

43. Ragnarsson J, Hardarson T, Snorrason SP "Ventricular dysrhythmias in middle-aged hypertensive men treated either with a diuretic agent or a beta-blocker." Acta Med Scand 221 (1987): 143-8

44. Holland OB, Kuhnert L, Pollard J, Padia M, Anderson RJ, Blomqvist G "Ventricular ectopic activity with diuretic therapy." Am J Hypertens 1 (1988): 380-5

45. Alfino PA, Thanavaro S, Kleiger RE, et al "Alpha-methyldopa and carotid-sinus hypersensitivity." N Engl J Med Aug (1981): 344-5

46. Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,

47. Duarte CG, Winnacker JL, Becker KL, Pace A "Thiazide-induced hypercalcemia." N Engl J Med 284 (1971): 828-30

48. Fichman MP, Vorherr H, Kleeman CR, Telfer N "Diuretic-induced hyponatremia." Ann Intern Med 75 (1971): 853-63

49. Gould L, Reddy CV, Zen B, Singh BK "Life-threatening reaction to thiazides." N Y State J Med 80 (1980): 1975-6

50. Pinnock CA "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978): 48

51. Bain PG, Egner W, Walker PR "Thiazide-induced dilutional hyponatraemia masquerading as subarachnoid haemorrhage ." Lancet 2 (1986): 634

52. Klimiuk PS, Davies M, Adams PH "Primary hyperparathyroidism and thiazide diuretics." Postgrad Med J 57 (1981): 80-3

53. Peters RW, Hamilton J, Hamilton BP "Incidence of cardiac arrhythmias associated with mild hypokalemia induced by low-dose diuretic therapy for hypertension." South Med J 82 (1989): 966-9,

54. Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5

55. Fager G, Berglund G, Bondjers G, Elmfeldt D, Lager I, Olofsson SO, Smith U, Wiklund O "Effects of anti-hypertensive therapy on serum lipoproteins. Treatment with metoprolol, propranolol and hydrochlorothiazide." Artery 11 (1983): 283-96

56. Rosenberg L, Shapiro S, Slone D, Kaufman DW, Miettinen OS, Stolley PD "Thiazides and acute cholecystitis." N Engl J Med 303 (1980): 546-8

57. Kuller L, Farrier N, Caggiula A, Borhani N, Dunkle S "Relationship of diuretic therapy and serum magnesium levels among participants in the Multiple Risk Factor Intervention Trial." Am J Epidemiol 122 (1985): 1045-59

58. Seelig CB "Magnesium deficiency in two hypertensive patient groups." South Med J 83 (1990): 739-42

59. Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10

60. Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2

61. Polanska AI, Baron DN "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978): 175-6

62. Benfield GF, Haffner C, Harris P, Stableforth DE "Dilutional hyponatraemia masquerading as subarachnoid haemorrhage in patient on hydrochlorothiazide/amiloride/timolol combined drug ." Lancet 2 (1986): 341

63. Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860

64. Papademetriou V, Price M, Notargiacomo A, Gottdiener J, Fletcher RD, Freis ED "Effect of diuretic therapy on ventricular arrhythmias in hypertensive patients with or without left ventricular hypertrophy." Am Heart J 110 (1985): 595-9

65. Kone B, Gimenez L, Watson AJ "Thiazide-induced hyponatremia." South Med J 79 (1986): 1456-7

66. Byatt CM, Millard PH, Levin GE "Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions." J R Soc Med 83 (1990): 704-8

67. Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R "Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy." Can Med Assoc J 121 (1979): 591-4

68. Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA "Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy." Ann Intern Med 103 (1985): 49-51

69. Chan W "Less common side effects of methyldopa." Med J Aust July (1977): 14-5

70. Weisenburger DD "Immunoblastic lymphadenopathy associated with methyldopa therapy." Cancer 42 (1978): 2322-7

71. Dupont A, Six R "Lupus-like syndrome induced by methyldopa." Br Med J 285 (1982): 693-4

72. Shirey RS, Bartholomew J, Bell W, Pollack B, Kickler TS, Ness PM "Characterization of antibody and selection of alternative drug therapy in hydrochlorothiazide-induced immune hemolytic anemia." Transfusion 28 (1988): 70-2

73. Bjornberg A, Gisslen H "Thiazides: A cause of necrotising vasculitis?" Lancet 2 (1965): 982-3

74. Ahmad S "Methyldopa and retroperitoneal fibrosis." Am Heart J 105 (1983): 1037-8

75. Nordstrom DM, West SG, Rubin RL "Methyldopa-induced systemic lupus erythematosus." Arthritis Rheum 32 (1989): 205-8

76. Klein MD "Noncardiogenic pulmonary edema following hydrochlorothiazide ingestion." Ann Emerg Med 16 (1987): 901-3

77. Levay ID "Hydrochlorothiazide-induced pulmonary edema." Drug Intell Clin Pharm 18 (1984): 238-9

78. Harries MG, Taylor AN, Wooden J, MacAuslan A "Bronchial asthma due to alpha-methyldopa." Br Med J June (1979): 1461

79. Hoss DM, Nierenberg DW "Severe shaking chills and fever following hydrochlorothiazide administration." Am J Med 85 (1988): 747

80. Magil AB "Drug-induced acute interstitial nephritis with granulomas." Hum Pathol 14 (1983): 36-41

81. Burry JN "Ulcerative lichenoid eruption from methyldopa." Arch Dermatol 112 (1976): 880

82. Beaudry C, Laplante L "Severe allergic pneumonitis from hydrochlorothiazide." Ann Intern Med 78 (1973): 251-3

83. Dorn MR, Walker BK "Noncardiogenic pulmonary edema associated with hydrochlorothiazide therapy." Chest 79 (1981): 482-3

84. Hoegholm A, Rasmussen SW, Kristensen KS "Pulmonary oedema with shock induced by hydrochlorothiazide: a rare side effect mimicking myocardial infarction." Br Heart J 63 (1990): 186

85. Alted E, Navarro M, Cantalapiedra JA, Alvarez JA, Blasco MA, Nunez A "Non-cardiogenic pulmonary edema after oral ingestion of hydrochlorothiazide ." Intensive Care Med 13 (1987): 364-5

86. Caldwell JR, Metts JC Jr "Tolerability." J Cardiovasc Pharmacol 3 (1981): s92-8

87. Magil AB, Ballon HS, Cameron EC, Rae A "Acute interstitial nephritis associated with thiazide diuretics. Clinical and pathologic observations in three cases." Am J Med 69 (1980): 939-43

88. Prupas HM, Brown D "Acute idiosyncratic reaction to hydrochlorothiazide ingestion." West J Med 138 (1983): 101-2

89. Goette DK, Beatrice E "Erythema annulare centrifugum caused by hydrochlorothiazide-induced interstitial nephritis." Int J Dermatol 27 (1988): 129-30

90. Grace AA, Morgan AD, Strickland NH "Hydrochlorothiazide causing unexplained pulmonary oedema." Br J Clin Pract 43 (1989): 79-81

91. DeBard ML "Methyldopa reaction simulating septic shock." Arch Intern Med 139 (1979): 196-7

92. Biron P, Dessureault J, Napke E "Acute allergic interstitial pneumonitis induced by hydrochlorothiazide [published erratum appears in Can Med Assoc J 1991 Sep 1;145(5):391]." Can Med Assoc J 145 (1991): 28-34

93. Yamadori A, Albert ML "Involuntary movement disorder caused by methyldopa." N Engl J Med May (1972): 610

94. Rosenblum AM, Montgomnery EB "Exacerbation of parkinsonism by methyldopa." JAMA 244 (1980): 2727-8

95. Robinson HN, Morison WL, Hood AF "Thiazide diuretic therapy and chronic photosensitivity." Arch Dermatol 121 (1985): 522-4

96. Vaillant L, Le Marchard D, Grognard C, et al "Photosensitivity to methyldopa." Arch Dermatol 124 (1988): 326-7

97. Wells JD, Kurtay M, Lochner JC, George WL "Granulomatous skin lesions and alpha-methyldopa." Ann Intern Med 81 (1974): 701-2

98. Brody HJ "Black tongue secondary to methyldopa therapy." Cutis 38 (1986): 187-8

99. Parodi A, Romagnoli M, Rebora A "Subacute cutaneous lupus erythematosus-like eruption caused by hydrochlorothiazide." Photodermatol 6 (1989): 100-2

100. Goodrich AL, Kohn SR "Hydrochlorothiazide-induced lupus erythematosus: a new variant?" J Am Acad Dermatol 28 (1993): 1001-2

101. Diffey BL, Langtry J "Phototoxic potential of thiazide diuretics in normal subjects." Arch Dermatol 125 (1989): 1355-8

102. Delevett AF, Recalde M "Diuretic-induced renal colic." JAMA 225 (1973): 992

103. Van Der Heide H, Haaft MA, Strickler BH "Pancreatitis caused by methyldopa." Br Med J 282 (1981): 1930-1

104. Smith BL, Tedeschi A, Lane CD "Pancreatitis with a twist." Hosp Pract (Off Ed) 23 (1988): 150,

105. Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967): 7-11

106. Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966): 291-6

107. Gloth FM, Busby MJ "Methyldopa-induced diarrhea: a case of iatrogenic diarrhea leading to request for nursing home placement." Am J Med 87 (1989): 480-1

108. Ramsay L, Wakefield VA, Harris E "Methyldopa-induced chronic pancreatitis." Practitioner 226 (1982): 1166, 1169

109. Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967): 136-8

110. Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966): 97-101

111. Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965): 383-5

112. Balizet L "Recurrent parathyroid adenoma. Association with prolonged thiazide administration." JAMA 225 (1973): 1238-9

113. Arze RS, Ramos JM, Rashid HU, Kerr DN "Amenorrhoea, galactorrhoea, and hyperprolactinaemia induced by methyldopa." Br Med J (Clin Res Ed) 283 (1981): 194

114. Leon AS, Agre J, McNally C, et al "Blood lipid effects of antihypertensive therapy: a double-blind comparison of the effects of methyldopa and propranolol." J Clin Pharmacol 24 (1984): 209-17

115. Tchen P, Luchins DJ, Rose RP "Possibility of depression as a side effect of methyldopa." Am J Psychiatry 147 (1990): 128

116. Labbate LA, Holzgang AJ "Manic syndrome after discontinuation of methyldopa." Am J Psychiatry 146 (1989): 1075-6

117. Endo M, Hirai KO, Ohara M "Paranoid-hallucinatory state induced in a depressive patient by methyldopa: a case report." Psychoneuroendocrinology 3 (1978): 211-5

118. Wurzelmann J, Frishman WH, Aronson M, et al "Neuropsychological effects of antihypertensive drugs." Cardiol Clin 5 (1987): 689-701

119. Ghosh SK "Methyldopa and forgetfulness." Lancet Jan (1976): 202-3

120. Murphy KJ "Bilateral renal calculi in patients receiving methyldopa." Med J Aust July (1976): 20-1

121. Taylor RG, Hoffbrand BI, Crisp AJ, et al "Plasma sex hormone concentrations in men with hypertension treated with methyldopa and/or propranolol." Postgrad Med J 57 (1981): 425-6

122. Newman RJ, Salerno HR "Sexual dysfunction due to methyldopa." Br Med J Oct (1974): 106

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web3)